There are 4 types on the market at the moment with several more in development
Growth Hormone Secretion The pituitary gland produces growth hormone, which is critical for different bodily functions in children and adults
The Bottom Line The Medicare GLP-1 Bridge starts July 1, 2026 and runs through the end of 2027, offering $50 access to specific weight loss drugs for beneficiaries who meet the BMI and health criteria and are enrolled in a Part D plan
We have to look at patients holistically, who have kidney disease and diabetes, to address the totality of risks, certainly progression to kidney failure, but also prevention of cardiovascular events and deaths. Ozempic and other GLP-1s will be compared to another diabetes drug class, SGLT-2 inhibitors Given Ozempics reduction of kidney disease events in the FLOW study, it seems likely that the GLP-1s will be used together with and compared against SGLT-2 inhibitor drugs
2019;36(S1):170
Understanding the Barrier to Receiving Weight Loss Injectables Our community members who are prescribed weight loss injectables containing the active ingredients semaglutide and tirzepatide have reported difficulties with consistently receiving their prescription
